LeMaitre Vascular, Inc. filings document a Nasdaq-listed medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Recent Form 8-K reports furnish quarterly operating and financial results, dividend-related updates, and related press release exhibits.
Proxy and governance filings cover board structure, director elections, executive compensation, advisory say-on-pay matters, and shareholder voting results. The filings also identify the company’s common stock, par value, Nasdaq Global Market listing under LMAT, and related public-company disclosure controls.
LEMAITRE VASCULAR INC (LMAT) reported that President and Director David B. Roberts received nine small grants of Dividend Equivalent Rights on September 3, 2026. These rights accrued on previously granted restricted stock unit and performance share unit awards and vest proportionately with those awards. Each dividend equivalent right is the economic equivalent of one share of common stock, carries no cash exercise price, and no Rule 10b5-1 trading plan is reported.
LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. Pellegrino Joseph P JR reported acquisition or exercise transactions in this Form 4 filing.
LEMAITRE VASCULAR INC (LMAT) reported that director Joseph P. Pellegrino, Jr. received several small awards of dividend equivalent rights on September 3, 2026, each tied to previously granted restricted stock unit and performance share unit awards. Each right is the economic equivalent of one share of common stock and vests proportionately with the underlying award.
LeMaitre Vascular Inc (LMAT) director Lawrence J. Jasinski reported the acquisition of several small blocks of Dividend Equivalent Rights on September 3, 2026. These rights accrued on previously granted restricted stock unit and performance share unit awards and are the economic equivalent of LeMaitre common shares, vesting proportionately with the underlying awards. No Rule 10b5-1 trading plan is reported.
LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. SHADAN MARTHA reported acquisition or exercise transactions in this Form 4 filing.
LEMAITRE VASCULAR INC (LMAT) director Martha Shadan reported several small awards of Dividend Equivalent Rights on September 3, 2026. These derivative rights accrued on previously granted restricted stock unit and performance share unit awards from December 2023, December 2024, and December 2025 and vest proportionately with those awards. Each right is the economic equivalent of one share of common stock, and no Rule 10b5-1 trading plan is reported.
LEMAITRE VASCULAR INC (LMAT) director John James O'Connor reported five acquisitions of dividend equivalent rights on September 3, 2026. The awards total a small fractional interest in common stock and all are direct derivative holdings tied to previously granted restricted stock unit and performance share unit awards.
According to the footnotes, each dividend equivalent right is the economic equivalent of one share of common stock and accrues on outstanding equity awards, vesting proportionately with those awards. No Rule 10b5-1 trading plan is reported, and no sales or disposals are listed in this filing.
LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. LeBlanc Dorian Paul reported acquisition or exercise transactions in this Form 4 filing.
LEMAITRE VASCULAR INC (LMAT) reported that its Chief Financial Officer, Dorian Paul LeBlanc, received small awards of additional Dividend Equivalent Rights on September 3, 2026 tied to prior restricted stock unit (RSU) grants. The awards reflect accrued dividend equivalents and are the economic equivalent of additional shares of common stock.
LEMAITRE VASCULAR INC (LMAT) reported that Chairman and CEO George W. LeMaitre acquired several small blocks of Dividend Equivalent Rights on September 3, 2026. These rights accrued on previously granted restricted stock unit and performance share unit awards from December 2022, December 2023, December 2024, and December 2025 and will vest proportionately with those underlying awards. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular’s common stock, and no Rule 10b5-1 trading plan is reported in connection with these accruals.
LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. Kamke Trent G reported acquisition or exercise transactions in this Form 4 filing.
LEMAITRE VASCULAR INC (LMAT) reported that Senior V. P., Operations, Trent G. Kamke received multiple dividend equivalent rights awards on September 3, 2026. The awards, in small fractional amounts tied to prior restricted stock unit and performance share unit grants, are each the economic equivalent of one share of common stock and vest proportionately with the underlying awards. No Rule 10b5-1 trading plan is reported.
LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. Roush John A reported acquisition or exercise transactions in this Form 4 filing.
LEMAITRE VASCULAR INC (LMAT) reported that director John A. Roush received multiple small grants of dividend equivalent rights on September 3, 2026. These rights accrued on previously granted restricted stock unit and performance share unit awards from December 2023, December 2024, and December 2025.
Each dividend equivalent right is disclosed as the economic equivalent of one share of common stock and will vest proportionately with the underlying stock unit or performance share awards. No cash price was paid for these derivative awards, and no Rule 10b5-1 trading plan is reported.
LEMAITRE VASCULAR INC (LMAT) director John A. Roush exercised employee stock options on September 1, 2026 to acquire 3,444 shares of common stock at an exercise price of $48.60 per share. Following the transaction, he held 7,386 shares directly and 181 shares indirectly through his wife. No Rule 10b5-1 trading plan is reported.